Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Novavax Inc — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 19.3× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Novavax Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Novavax Inc for 59 Days on average.
| MSTZ | NVAX | |
|---|---|---|
Market Cap | $94.46M | $1.82B |
Volume | 104,717,733 | 6,198,505 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $12.56 |
52-Week Low | $2.29 | $6.22 |
Typical Hold Time | 8 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $2.62, down 1.5% today, with technical indicators showing a bearish bias as moving averages signal selling pressure while oscillators remain neutral. The stock faces resistance at $3 with support at $2, indicating a tight trading range. Recent ETF coverage highlights its inclusion in leveraged fund discussions, though specific company fundamentals remain undisclosed in available data.
The outlook for MSTZ hinges on upcoming financial disclosures to clarify valuation metrics like P/E and profitability. Key risks include limited public financial data and market volatility. Investors await earnings reports to assess growth potential amid current technical weakness.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
